Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 7/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | BRD2 | P25440 | 1/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.40 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.40 |
| ▸ | BAD | Q92934 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4996274 | 0.88 | PTGER3 (0.43) | PTGER3PPARGBRD4BRD2BRD3 | |
| SCHEMBL4994979 | 0.87 | LMNA (0.46) | PTGER3PPARGMAPTTHRBLMNA | |
| SCHEMBL4986527 | 0.85 | BRD4 (0.47) | BRD4BRD2BRD3BRDTMCL1 | |
| SCHEMBL4994721 | 0.82 | CYP1A2 (0.44) | BRD4BRD2BRD3BRDTMCL1 | |
| SCHEMBL4996102 | 0.81 | BRD4 (0.44) | PTGER3BRD4BRD2BRD3BRDT | |
| SCHEMBL4997127 | 0.80 | BRD4 (0.52) | BRD4BRD2BRD3BRDTMAPT | |
| SCHEMBL4986221 | 0.78 | LIPG (0.49) | BRD4BRD2BRD3BRDTMAPT | |
| SCHEMBL4993505 | 0.78 | BRD4 (0.48) | PTGER3BRD4BRD2BRD3BRDT | |
| SCHEMBL5151189 | 0.77 | RXRA (0.58) | RXRARXRBRXRGMAPTLMNA | |
| SCHEMBL4553891 | 0.75 | MCL1 (0.49) | BRD4BRD2BRD3BRDTMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | PTGER3 80/4885PPARG 2064/4885RXRA 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.